Skip to content
4.7 °Cforecast >
Clear
Jobs | Contact | Tip line: 705-673-0123

Long-term care seniors focus of first major medical weed study

Canopy Growth announces partnership with Ontario Long Term Care Association for six-month pilot of potential pot benefits, best practices, for residents living in long-term care facilities
0

A medical marijuana pilot study that could register up to 500 seniors living in long-term care facilities is set to roll out in Ontario, making it not only the biggest but the first of its kind. Cannabis and cannabis oil will become legal in Canada Oct. 17.

Cannabis producer Canopy Growth yesterday announced it is partnering with the Ontario Long Term Care Association to conduct the six-month study to better learn how medical cannabis use could potentially replace other treatments for pain and cognitive function. The pilot also aims to identify best practices in the areas of safety and quality for long-term care facilities that implement a medical marijuana program.

“Medical cannabis is currently prescribed for residents as appropriate, but it’s still an emerging area,” long-term care association CEO Candace Chartier said in a media release. “Through this partnership and pilot study, we hope to provide more clarity to long-term care clinicians and frontline staff about the use of medical cannabis for residents.”

Newmarket has four long-term care facilities, including Eagle Terrace Long Term Care Facility, Mackenzie Place Long Term Care, Southlake Residential Care Village, and Newmarket Health Centre. It has not been confirmed if any of the local facilities will take part in the pilot study.

The senior population in York Region is growing faster than any other cohort, and by 2026 the number of seniors is expected to outnumber that of children, according to the Regional Municipality of York.

The long-term care association, which represents about 70 per cent of Ontario’s 630 long-term care homes, will lead the pilot study and is expected to present its findings sometime next spring. Canopy Growth will provide all the product from its Spectrum Cannabis brand.

According to the association’s This is Long Term Care 2018 report, two out of three long-term care residents have been diagnosed with Alzheimer’s disease or another dementia. About 90 per cent of residents, overall, have some form of cognitive impairment from other causes as well, such as stroke and memory loss, the report states.

“There is clearly an interest in the long-term care space to explore medical cannabis as an alternative to traditional medications for pain and degenerative cognitive function,” Canopy Growth president and CEO Mark Zekulin said in the announcement. “The pilot study we’ve announced today is the first step in developing an evidence-based, best practice approach to medical cannabis that will result in consistent care for thousands of seniors.”

Meanwhile, the Town of Newmarket has not yet made a decision if it will allow bricks-and-mortar retail pot shops in the community after legalization. It has until Jan. 22, 2019 to opt-out of the province’s retail plan for the product.




Comments